News
Experimental Cell Therapies for COVID-19
ThermoGenesis Holdings Announces 2020 Year End Financial Results and Provides Corporate Update
Current and Future Approaches to Immunotherapy
ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2020 and Provide a Corporate Strategic Update
ThermoGenesis Leadership & Growth Throughout the Decades
ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry
Frequently Asked Questions About Cell and Gene Therapies
ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System — PXP™-LAVARE — for CAR-T Manufacturing
The Successes and Challenges of CAR T-cell Therapy
Bone Marrow Aspirate Concentrate vs. Surgical Intervention
ThermoGenesis Holdings to Participate at the H.C. Wainwright BIOCONNECT 2021 Conference
The Role Testing Plays in the Management of the COVID-19 Pandemic
ThermoGenesis Provides Regenerative Medicine Solutions
The Technology Behind Bone Marrow Cellular Processing: The PXP® System
ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2020 and Provides Corporate Update
ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2020 and Provide a Corporate Strategic Update
Facilitating the ‘Vaccine Era’ of COVID-19 Response: ThermoGenesis to Receive U.S. Patent for Breakthrough Serological Test Reader Technology
ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic
ThermoGenesis Holdings to Participate in Investor Conferences in September
